Karyopharm Therapeutics Inc. KPTI

Latest FY: 2025 Healthcare Biotechnology
Market Price $1.76
Market Cap $39.89M
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑0.6% YoY
$146.07M
3-Yr CAGR: -2.4%
Net Income ↓-156.5% YoY
-$196.04M
Net Margin: -134.2%
Free Cash Flow ↑40.9% YoY
-$75.37M
FCF Yield: -188.96%
EPS (Diluted) ↓-1,828.0% YoY
$-17.93
Basic: $-17.93
Return on Equity Efficiency
N/A
ROA: -180.8%
⚡ N/A due to negative equity (share buybacks or other)

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (KPTI)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2017: Revenue YoY (+942.2%) is identical to Gross Profit YoY (+942.2%). Verify the underlying Revenue and Gross Profit values for FY 2017 and FY 2016.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $0.2M $0.2M $-109.6M 0.00% $-84.4M $-84.5M
FY 2017 $1.6M +942.2% $1.6M $-129.0M -17.7% 0.00% $-73.7M $-73.8M +12.6%
FY 2018 $30.3M +1,790.1% $27.8M $-178.4M -38.3% 0.00% $-159.1M $-161.5M -118.9%
FY 2019 $40.9M +34.8% $25.2M $-199.6M -11.9% 0.00% $-190.8M $-191.0M -18.3%
FY 2020 $108.1M +164.3% $80.9M $-196.3M +1.7% $-2.72 0.00% $-160.2M $-160.4M +16.0%
FY 2021 $209.8M +94.1% $183.8M $-124.1M +36.8% $-1.65 +39.3% 0.00% $-107.1M $-107.3M +33.1%
FY 2022 $157.1M -25.1% $132.1M $-165.3M -33.2% $-2.02 -22.4% 0.00% $-149.6M $-149.7M -39.5%
FY 2023 $146.0M -7.0% $122.2M $-143.1M +13.4% $-1.25 +38.1% 0.00% $-92.7M $-92.7M +38.0%
FY 2024 $145.2M -0.5% $107.8M $-76.4M +46.6% $-0.93 +25.6% 0.00% $-127.5M $-127.6M -37.6%
FY 2025 $146.1M +0.6% $100.2M $-196.0M -156.5% $-17.93 -1,828.0% 0.00% $-75.4M $-75.4M +40.9%
$

Valuation

Market Price $1.76
Market Cap $39.89M
Enterprise Value -$20.65M
P/E Ratio N/A
P/B Ratio N/A
FCF Yield -188.96%
Dividend Yield N/A
Shares Outstanding 22,662,900
%

Profitability & Margins

Gross Margin 68.61%
Operating Margin -62.10%
Net Margin -134.21%
Return on Equity (ROE) N/A (Negative Equity)
Return on Assets (ROA) -180.82%
Asset Turnover 1.35x
Revenue 3-Yr CAGR -2.39%
🛡️

Financial Health & Liquidity

Current Ratio 1.12
Cash Ratio 0.66
Debt / Equity -0.000
Debt / Assets 0.000
Cash & Equivalents $60.54M
Total Debt N/A
Book Value / Share $-12.93
💧

Cash Flow Efficiency

Operating Cash Flow -$75.37M
Capital Expenditures (CapEx) N/A
Free Cash Flow -$75.37M
OCF / Revenue -51.60%
FCF / Revenue -51.60%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-17.93
EPS (Basic) $-17.93
Dividends / Share N/A
Book Value / Share $-12.93
EPS YoY Growth -1,827.96%
🏛️

Balance Sheet (FY 2025)

Total Assets $108.42M
Total Liabilities $401.34M
Stockholders' Equity -$292.93M
Current Assets $103.15M
Current Liabilities $92.06M